Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elbasvir - Merck & Co

Drug Profile

Elbasvir - Merck & Co

Alternative Names: MK-8742

Latest Information Update: 27 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Amides; Antivirals; Benzoxazines; Carbamates; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Pyrrolidines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 27 Sep 2021 No development reported - Phase-II for Hepatitis C (Combination therapy) in Germany, Australia, Canada, Israel, Switzerland, New Zealand, United Kingdom (PO) (NCT02332720)
  • 27 Sep 2021 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Spain, Denmark, Sweden, USA, Italy, Puerto Rico, Lithuania, France, Poland, Australia, Austria, Canada, Germany, Israel, New Zealand, United Kingdom (PO) (NCT02332707)
  • 05 Oct 2017 Nippon Medical School Chiba Hokusoh Hospital plans a clinical trial for Hepatitis C (Combination therapy) in Japan (UMIN000029262)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top